Interactions
Cannabis and medicines: which interactions matter?
Anyone using medical cannabis often also takes other medicines. Interactions can occur in the process.
Anyone using medical cannabis often also takes other medicines. Interactions can occur in the process. This does not mean, however, that cannabis and other medicines are fundamentally incompatible. What matters is which active substances are combined, at what dose and over what period. The distinction between THC and CBD is particularly important: the two are processed differently in the body and can affect other medicines in different ways.1,2
For safe treatment, the doctor therefore needs complete information above all. Non-prescription CBD oils, sleeping pills and occasionally used cannabis also belong in the medication history. A possible interaction is a reason to look more closely, but not automatically a reason to refuse treatment.
How do interactions arise?
There are two basic mechanisms. In a pharmacokinetic interaction, one active substance changes how quickly another is absorbed, broken down or excreted. As a result, its concentration in the blood may rise or fall. In a pharmacodynamic interaction, the effects of two substances influence each other directly, for example when both cause tiredness or impair the ability to react.1,2
Enzymes of the cytochrome P450 family, CYP for short, are responsible for breaking down many medicines. The enzymes particularly relevant to cannabis include CYP2C19, CYP2C9 and CYP3A4. If such an enzyme is inhibited, a medicine can accumulate in the body and act more strongly or for longer. With active substances that first have to be activated by an enzyme, a weakened effect is also possible. Whether this actually leads to a clinical problem depends on the medicine in question and the dosage.1,3
THC and CBD: same origin, different interactions
CBD is particularly relevant to interactions via CYP enzymes. In a controlled study with 18 healthy adults, a high single oral dose of 640 mg CBD together with 20 mg THC inhibited mainly CYP2C19, and also CYP2C9, CYP3A4 and CYP1A2. The comparison dose of 20 mg THC without CBD showed no corresponding inhibition in this study. The results are clear evidence of possible CBD-related interactions, but cannot simply be transferred to lower doses.1
Clinically, THC is more often in the foreground because of its direct effects on perception, attention, circulation and tiredness. With sedatives or sleeping pills, these effects can add up. THC itself is also broken down via CYP2C9 and CYP3A4, among others: other medicines can therefore also change the effect or breakdown of THC. CBD is not intoxicating, but that by no means makes it free of drug interactions.1,2
Examples from everyday medical practice
Blood thinners: watch the clotting
With certain anticoagulant medicines, interactions can have particularly serious consequences. For warfarin, there are individual case reports in which the INR value rose under cannabis or CBD. This points to stronger anticoagulation and a possible risk of bleeding. The evidence is limited and does not allow any statement about how often this happens. For phenprocoumon (Marcoumar) and most newer anticoagulants, the clinical data are considerably thinner.3,4
Anyone taking a blood thinner therefore does not automatically have to rule out cannabis. A medical review before starting or when the dose changes makes sense; depending on the preparation, additional INR checks or other adjustments may be needed, for example. Blood thinners should not be stopped on your own.
Psychotropic medicines and sleeping pills: consider effect and breakdown
With antidepressants, antipsychotics, benzodiazepines and sleeping pills, different interactions are conceivable depending on the active substance. Some of these medicines are metabolised via CYP enzymes. At the same time, THC and central nervous system depressants can intensify tiredness, dizziness and impaired ability to react. Especially when several preparations are taken at the same time, an individual assessment is therefore important.2,4
A well-documented example is the combination of CBD with clobazam, a benzodiazepine used mainly in the treatment of epilepsy: via CYP2C19, CBD can considerably increase the concentration of the active clobazam metabolite and thereby intensify drowsiness or sedation. This cannot be transferred to all psychotropic medicines. What always matters is the specific active substance, not just the group of medicines.5
Valproate and tacrolimus: two clinically documented examples
With valproate, an active substance for epilepsy that is also used in bipolar disorder, an interaction with CBD is clinically documented. However, it cannot be explained via CYP enzymes. In the authorisation studies of a CBD medicine, liver values (transaminases) rose considerably more often when valproate was also taken. The product information therefore provides for liver value checks; if values are considerably raised, a dose adjustment or stopping one of the two medicines may be considered.5
Tacrolimus prevents rejection of the new organ after an organ transplant. The active substance is broken down via CYP3A4 and has a narrow therapeutic range: even small changes in the blood level can affect its effect or tolerability. In one case report, the dose-adjusted tacrolimus concentration rose to roughly three times its level under very high CBD doses of 2,000 to 2,900 mg per day. A single case says nothing about how often this happens. It does show, however, why the tacrolimus level should be closely monitored when CBD is added, its dose changes or it is stopped.8
Chemotherapy and cancer therapies: separating theory and findings
Many cancer medicines are broken down via the same CYP enzymes as THC and CBD, above all via CYP3A4, and some have a narrow therapeutic range. Theoretically, this means that cannabis or CBD could change their blood levels. Such a theoretical CYP interaction, however, is not yet a proven interaction. Whether it plays a clinical role depends heavily on the individual active substance, the dosage and the form of use. For most combinations, there are no studies in humans.4
Where data are available, they vary. In a study with 24 cancer patients, cannabis tea taken over 15 days did not substantially change the blood levels of the chemotherapy drugs irinotecan and docetaxel. This cannot be transferred to higher CBD doses or other active substances. In a retrospective observational study with 140 people on the immunotherapy nivolumab, those who also used cannabis responded to treatment less often; there was no difference in survival. Whether cannabis was the cause is something such a study cannot clarify.9,10
During cancer therapy, any use of cannabis or CBD therefore belongs in the conversation with the oncology team before it begins or changes. Do not stop either the cancer therapy or a prescribed cannabis medicine on your own.
General anaesthesia and procedures: inform the anaesthesia team
Before an operation, an endoscopy with sedation or a general anaesthetic, the treatment team should know whether cannabis or CBD is being used, including products not prescribed by a doctor. Relevant are the type of product, THC and CBD content, frequency, form of use and time of the last intake.2
Cannabis can affect, among other things, circulatory reactions and the effect of anaesthetics or painkillers. With regular use, the anaesthetic doses needed may differ; the evidence so far is, however, limited. Acute cannabis intoxication can be a reason to postpone a planned procedure. Whether ongoing medically prescribed therapy should be paused before a procedure is decided individually by the anaesthesia team, not by the person concerned on their own.2
Not every possible interaction is a contraindication
The strength of an interaction cannot be read solely from the fact that two substances are metabolised via the same CYP enzyme. Besides the exact medicine, what counts are the THC and CBD dose, the duration of use, the route of intake, liver function, additional medicines and the start or stopping of a treatment. Accompanying tobacco use and changes in smoking behaviour can also be relevant for individual medicines.1,2,4
In practice, this means: using cannabis together with blood thinners or psychotropic medicines is not prohibited across the board. Individual combinations may require closer monitoring, a dose adjustment or the choice of a different medicine. With others, no clinically significant interaction is to be expected. What matters is the individual medical weighing of benefits and risks, especially with medicines that have a narrow therapeutic range.3,4
How doctors can check for interactions
The basis is a complete medication plan: prescription medicines, non-prescription preparations, herbal remedies, CBD products and, where applicable, non-prescribed cannabis. In addition, information that is as precise as possible on THC and CBD content, dose, frequency and form of use is needed.
A helpful tool is CANN-DIR (CANNabinoid Drug Interaction Review) from Penn State University. There, THC, CBD or a combination can be checked together with other medicines for possible metabolic interactions. The database supports structured research; however, it does not cover all conceivable interactions, and in particular does not provide a complete assessment of additive sedative effects or of perioperative risk. A flag in the tool does not automatically mean that the combination is prohibited; equally, the absence of a flag does not guarantee freedom from risk.6,7
Depending on the result, the treating doctor may adjust the dose, choose an alternative medicine, watch for side effects or check laboratory values or drug levels. If several practices are involved, it is important that the information reaches everyone treating you.
Speak openly about cannabis, even if it is not prescribed
For the medical assessment, what counts is not why someone uses cannabis, but what is actually taken. This also applies to self-purchased CBD products and non-prescribed cannabis. If this information is left out for fear of being judged, the interaction check may be incomplete. Honest information creates the basis for adjusting treatment safely; changes to existing medicines should never be made on your own.
Further information on medical advice: Cannabis therapy at evidena
This article is for general information and does not replace individual medical advice.
Sources
- Bansal S et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023;114(3):693–703. doi:10.1002/cpt.2973
- Shah S et al. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med. 2023;48(3):97–117. doi:10.1136/rapm-2022-104013
- Smythe MA et al. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy. 2023;43(12):1327–1338. doi:10.1002/phar.2881
- Nachnani R et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. doi:10.3389/fphar.2024.1282831
- Fachinformation Epidyolex 100 mg/ml (Cannabidiol), Abschnitte 4.4 und 4.5: Leberwerte und Valproat, Wechselwirkungen mit Clobazam und CYP2C19. Electronic Medicines Compendium (UK)
- Kocis PT et al. CANNabinoid Drug Interaction Review (CANN-DIR). Med Cannabis Cannabinoids. 2023;6(1):1–7. doi:10.1159/000528528
- Penn State College of Medicine: CANN-DIR, Online-Werkzeug für mögliche metabolische Wechselwirkungen von THC und CBD mit anderen Medikamenten
- Leino AD et al. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944–2948. doi:10.1111/ajt.15398
- Engels FK et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 2007;12(3):291–300. doi:10.1634/theoncologist.12-3-291
- Taha T et al. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist. 2019;24(4):549–554. doi:10.1634/theoncologist.2018-0383